Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and Perspectives
Open Access
- 1 May 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4958
Abstract
Systemic inflammation and coronary microvascular endothelial dysfunction are essential pathophysiological factors in heart failure (HF) with preserved ejection fraction (HFpEF) that support the use of statins. The pleiotropic properties of statins, such as anti-inflammatory, antihypertrophic, antifibrotic, and antioxidant effects, are generally accepted and may be beneficial in HF, especially in HFpEF. Numerous observational clinical trials have consistently shown a beneficial prognostic effect of statins in patients with HFpEF, while the results of two larger trials in patients with HFrEF have been controversial. Such differences may be related to a more pronounced impact of the pleiotropic properties of statins on the pathophysiology of HFpEF and pro-inflammatory comorbidities (arterial hypertension, diabetes mellitus, obesity, chronic kidney disease) that are more common in HFpEF. This review discusses the potential mechanisms of statin action that may be beneficial for patients with HFpEF, as well as clinical trials that have evaluated the statin effects on left ventricular diastolic function and clinical outcomes in patients with HFpEF.Keywords
All Related Versions
Funding Information
- the Ministry of Health of the Russian Federation (124020200111-6)
This publication has 201 references indexed in Scilit:
- Statins and the risk of polyneuropathy: A systematic review and two meta‐analysesMuscle & Nerve, 2021
- Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialEuropean Journal of Heart Failure, 2020
- Impact of Statins on Cellular Respiration and De-Differentiation of Myofibroblasts in Human Failing HeartsESC Heart Failure, 2019
- Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure RegistryClinical Research in Cardiology, 2019
- Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2018
- Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching studyHeart and Vessels, 2017
- Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological studyEuropean Journal of Clinical Pharmacology, 2012
- Statin Therapy in Patients with Diastolic Heart FailureClinical Cardiology, 2010
- The IFN‐γ‐induced transcriptional program of the CIITA gene is inhibited by statinsEuropean Journal of Immunology, 2008
- Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPasesEuropean Journal of Immunology, 2006